Rakuten on May 18
Zhengye Biotechnology Holding Limited（正业生物）日前更新招股书，准备在美国纳斯达克上市。
Zhengye Biotech has obtained the notice of filing for overseas issuance and listing. Zhengye Biotech intends to issue no more than 1,312,908 ordinary shares.
Zhengye Biotech is one of the first enterprises designated by the Ministry of Agriculture to produce highly pathogenic porcine PRRS inactivated vaccine and rabies purified lyophilized inactivated vaccine (Flury LEP strain), and is designated by the Ministry of Agriculture to produce swine fever splenic drenching attenuated vaccine.
According to the prospectus, Zhengye Biotech's revenue in 2023 will be 211 million yuan, down 18.85% from 260 million yuan in the same period last year; Gross profit was $130 million, compared to $154 million in the same period last year.
Zhengye Biotech's operating profit in 2023 will be 44.99 million yuan, down 31.66% from 65.83 million yuan in the same period of the previous year; The net profit was 37.51 million yuan, down 32.7% from 55.74 million yuan in the same period last year.
As of December 31, 2023, the cash and cash equivalents held by Zhengye Biotech were 27.19 million yuan (approximately 3.83 million US dollars).
IPO前,Zhenfa Han持股为97.5818%,Wei Lian持股为0.1819%,Yawen Dong持股为0.2728%,Yuyou He持股为0.1096%。
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.